Bolt Biotherapeutics, Inc.
BOLT evidence brief
What we can confirm
- Market Cap:
- $7.6M
What it means
What to watch
Prepared research question
What matters most for BOLT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BOLT
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, including immune-stimulating antibody conjugates and dectin-2 agonists, with a lead program BDC-4182 in Phase 1 dose escalation [news · published 2026-03-12].
Key risk: Cash runway limited
Market Cap
$7.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for Bolt Biotherapeutics, Inc..
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, including immune-stimulating antibody conjugates and dectin-2 agonists, with a lead program BDC-4182 in Phase 1 dose escalation [news · published 2026-03-12].
- Cash & equivalents of $12.9M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net loss of -$7.7M for the six months ended June 30, 2026 [sec].
- Lead program BDC-4182 (immune-stimulating antibody conjugate) in Phase 1 dose escalation, with initial clinical data expected in 3Q 2026 [news · published 2026-03-12].
- BDC-3042 (dectin-2 agonist) Phase 1 dose-escalation study ongoing; first patient dosed in October 2023 [sec_mda · as of 2026-03-12].
- Independent auditor expressed substantial doubt about going concern as of December 31, 2025 [sec_mda · as of 2026-08-11].
What works
- First-in-class immune-stimulating antibody conjugate BDC-4182 is in Phase 1 dose escalation, with initial clinical data expected in 3Q 2026, indicating a novel approach in cancer immunotherapy [news · published 2026-03-12].
- BDC-3042, a dectin-2 agonist, has shown ability to repolarize tumor-associated macrophages in preclinical models, suggesting a differentiated mechanism [sec_mda · as of 2026-03-12].
- The company has presented data on its claudin 18.2 Boltbody ISAC program at SITC annual meetings in 2023, 2024, and 2025, demonstrating ongoing scientific engagement [sec_mda · as of 2026-03-12].
What to weigh
- Cash & equivalents of $12.9M as of 2026-06-30 is low relative to prior quarters ($23.9M as of March 31, 2026) and may be insufficient to fund operations beyond the near term [sec] [news · published 2026-05-12].
- The company has no revenue ($0.0M) and a net loss of -$7.7M for the six months ended June 30, 2026, indicating ongoing cash burn without product sales [sec].
- Independent auditor expressed substantial doubt about the company's ability to continue as a going concern as of December 31, 2025 [sec_mda · as of 2026-08-11].
- The company acknowledges it will need to raise additional capital to continue program advancement, and funding requirements are expected to grow with clinical progress [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Going concern doubt by auditor
“our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements, as of and for the year ended, December 31, 2025, describing the existence of substantial doubt about our ability to continue as a going concern”
SEC MD&A · August 11, 2026
BDC-4182 initial data expected in 3Q 2026
“initial clinical data expected in 3Q 2026”
News · March 12, 2026
Catalyst timeline
- 2020-02-24 · Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors — Phase 2 start for BDC-1001; watch for any updates on this HER2-targeted program.
- 2023-10-11 · Phase 1/2 Study of BDC-3042 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies — Phase 1 start for BDC-3042; initial data may inform dectin-2 agonist potential.
- 2023-11-30 · Phase 2 Study of BDC-1001 as a Single Agent and in Combination With Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Deruxtecan — Phase 2 start for BDC-1001 in a specific breast cancer setting; efficacy data will be key.
- 2024-11-20 · Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced — Phase 2 start for TORL-1-23; note this appears unrelated to Bolt's core programs but is listed in catalyst timeline.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $12.9M as of 2026-06-30 may be insufficient to fund operations beyond near term without additional capital [sec].
- No revenue, ongoing losses — Zero revenue and net loss of -$7.7M for six months ended June 30, 2026, indicating continued cash burn [sec].
- Going concern uncertainty — Auditor expressed substantial doubt about ability to continue as going concern as of Dec 31, 2025 [sec_mda · as of 2026-08-11].
- Clinical trial cost uncertainty — Future capital needs depend on uncertain clinical trial costs, timing, and outcomes [sec_mda · as of 2026-08-11].
What to watch
- Initial clinical data for BDC-4182 expected in 3Q 2026 [news · published 2026-03-12].
- Ability to raise additional capital through equity or partnering to extend cash runway [sec_mda · as of 2026-05-12].
- Progress of BDC-3042 Phase 1 dose-escalation study and any updates on tumor-associated macrophage repolarization [sec_mda · as of 2026-03-12].
- Any changes in cash position or auditor going concern status in future quarterly filings.
Sources: Catalysts · News · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Bolt Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bolt Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$2.5M
| Holder | Shares | Value |
|---|---|---|
| sofinnova investments, inc. | 137,721 | $556K |
| renaissance technologies llc | 77,225 | $312K |
| vivo capital, llc | 72,414 | $293K |
| pivotal bioventure partners investment advisor llc | 42,581 | $172K |
| t3 companies, llc | 38,000 | $154K |
| board of trustees of the leland stanford junior university | 35,977 | $145K |
| pfizer inc | 31,305 | $137K |
| lynx1 capital management lp | 30,800 | $124K |
| nan fung group holdings ltd | 29,250 | $118K |
| geode capital management, llc | 28,791 | $116K |
Showing top 10 of 24 institutional holders of Bolt Biotherapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.4%
- Days to cover
- 0.3
- Shares short
- 6,999
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BOLT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, including immune-stimulating antibody conjugates and dectin-2 agonists, with a lead program BDC-4182 in Phase 1 dose escalation [news · published 2026-03-12].
Who is the CEO of Bolt Biotherapeutics, Inc.?
Mr. William P. Quinn is the chief executive officer of Bolt Biotherapeutics, Inc. (BOLT).
Where is Bolt Biotherapeutics, Inc. headquartered?
Bolt Biotherapeutics, Inc. (BOLT) is headquartered in Redwood City, CA, United States.
What therapeutic areas does Bolt Biotherapeutics, Inc. focus on?
Bolt Biotherapeutics, Inc. develops therapies across Oncology, Cardiovascular, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.